阅读说明：本技术 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合 (FGF21 compound/GLP-1R agonist combinations with optimized activity ratio ) 是由 K·科纳 于 2019-06-21 设计创作，主要内容包括：本发明涉及包含FGF21(成纤维细胞生长因子21)化合物和GLP-1R(胰高血糖素样肽-1受体)激动剂的组合、药物组合物和融合分子,其具有优化的GLP-1R激动剂/FGF21化合物活性比率。本发明还涉及所述组合、药物组合物和融合分子作为特定用于治疗肥胖症、体重超重、代谢综合征、糖尿病、糖尿病视网膜病变、高血糖症、血脂异常、非酒精性脂肪性肝炎(NASH)和/或动脉粥样硬化的药物的用途。(The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist, having an optimized GLP-1R agonist/FGF 21 compound activity ratio. The invention also relates to the use of said combinations, pharmaceutical compositions and fusion molecules as a medicament in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.)